PRGO vs. JAZZ, CORT, SUPN, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJ
Should you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry.
Perrigo (NYSE:PRGO) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.
Perrigo presently has a consensus price target of $40.67, indicating a potential upside of 47.72%. Jazz Pharmaceuticals has a consensus price target of $192.75, indicating a potential upside of 83.14%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Perrigo.
95.9% of Perrigo shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.7% of Perrigo shares are held by company insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Perrigo's net margin of -0.17%. Jazz Pharmaceuticals' return on equity of 27.86% beat Perrigo's return on equity.
In the previous week, Perrigo had 11 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 21 mentions for Perrigo and 10 mentions for Jazz Pharmaceuticals. Perrigo's average media sentiment score of 0.59 beat Jazz Pharmaceuticals' score of 0.45 indicating that Perrigo is being referred to more favorably in the media.
Jazz Pharmaceuticals received 334 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.56% of users gave Jazz Pharmaceuticals an outperform vote while only 66.78% of users gave Perrigo an outperform vote.
Perrigo has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Jazz Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Jazz Pharmaceuticals beats Perrigo on 12 of the 17 factors compared between the two stocks.
Get Perrigo News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
